Lilly Targets Actavis In Latest Cymbalta Patent Suit
Eli Lilly and Co. added a fifth generic-drug maker to its bid to block competing versions of its antidepressant Cymbalta Tuesday, suing Actavis Elizabeth LLC over a patent for the blockbuster...To view the full article, register now.
Already a subscriber? Click here to view full article